Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Exon 51 is one of 79 exons in the *DMD* gene, which encodes the protein dystrophin. Mutations resulting in loss of the normal reading frame at or near exon 51 cause Duchenne muscular dystrophy (DMD), a severe, progressive muscle-wasting disease. Exon skipping therapy—most notably with eteplirsen—uses synthetic antisense oligonucleotides to bind pre-mRNA and induce the exclusion (skipping) of exon 51 during mRNA processing. This restores the reading frame in selected patients, enabling production of a truncated but functional dystrophin protein, often resulting in a less severe Becker muscular dystrophy–like phenotype. Exon 51 itself is not a functional molecule or protein but represents a locus for gene-editing or RNA-splicing based interventions.
Antisense-mediated exon skipping — antisense oligonucleotides (AONs) bind to pre-mRNA at exon 51 to alter splicing, excising exon 51, restoring the reading frame, and permitting the expression of truncated but functional dystrophin protein
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dystrophin Exon 51.